Variable | IIPs (n = 70) | CTD-ILD (n = 49) | CHP (n = 10) | p-value |
---|---|---|---|---|
Age, years, mean ± SD | 69.4 ± 8.9 | 66.5 ± 11.4 | 71.3 ± 7.5 | 0.185 |
Male sex, n (%) | 56 (80)* | 13 (27) | 7 (70) | < 0.001 |
Current smoker, n (%) | 9 (13) | 1 (2) | 0 (0) | 0.082 |
Pack-years of smoking, median (IQR) | 40 (16–52) | 0 (0–15)†| 16 (4–35) | < 0.001 |
Body mass indexa, mean ± SD | 24.1 ± 3.3 | 23.1 ± 3.6 | 23.2 ± 2.0 | 0.279 |
FSSG score, median (IQR) | 3 (1–7) | 6 (2–12)†| 4 (1–4) | 0.010 |
MRC chronic dyspnoea scale, median (IQR)b | 1 (1–2) | 1 (1–2) | 1 (1–3) | 0.824 |
Pulmonary function tests, % predicted, median (IQR)c | ||||
 FEV1 | 82.9 (74.3–94.4) | 94.2 (85.6–107.8)†| 87.6 (78.8–90.1) | 0.012 |
 FVC | 85.2 (74.2–97.3) | 93.6 (80.2–106.1) | 73.6 (68.8–93.3) | 0.090 |
 TLC | 70.1 (64.3–85.8) | 97.1 (79.8–104.1)†‡ | 68.5 (54.4–72.1) | < 0.001 |
 DLCO | 49.2 (38.8–58.9) | 55.2 (48.1–66.6)†| 56.0 (37.2–62.9) | 0.024 |
Composite Physiologic Index, median (IQR)c | 43.2 (30.5–52.8) | 34.8 (31.1–47.5) | 43.5 (34.5–51.2) | 0.157 |
Medication, n (%) | ||||
 Glucocorticoid | 9 (13)* | 30 (61) | 4 (40) | < 0.001 |
 Antifibrotic agent | 21 (30)* | 0 (0) | 2 (20) | < 0.001 |
 Proton pump inhibitor | 21 (30)* | 26 (53) | 4 (40) | 0.040 |
VAS score for cough, mm, median (IQR) | ||||
 Intensity | 31 (17–55)§ | 24 (8–46) | 18 (6–20) | 0.048 |
 Frequency | 24 (10–46) | 13 (5–30) | 10 (3–18) | 0.060 |
Leicester Cough Questionnaire score, median (IQR) | ||||
 Physical | 6.1 (5.5–6.4) | 6.0 (5.0–6.5) | 6.3 (6.0–6.6) | 0.311 |
 Psychological | 6.6 (5.9–7.0) | 6.3 (5.3–7.0) | 6.8 (6.1–7.0) | 0.378 |
 Social | 6.8 (6.0–7.0) | 6.5 (5.3–7.0) | 6.9 (6.0–7.0) | 0.539 |
 Total | 19.3 (17.5–20.4) | 18.7 (15.4–20.5) | 19.6 (18.3–20.6) | 0.447 |